A review of therapies of liver metastasis from colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.06.014

Abstract

Abstract:

Liver metastasis occurs frequently among patients with colorectal cancer. In the natural progression of colorectal cancer, up to 50% patients appear liver metastasis. Liver metastasis is the main reason which leads to death. Hepatectomy is the only chance to cure. However, most patients can't be radically resected when diagnosed. Chemotherapy, convertible chemotherapy, interventional therapy, radiotherapy and Chinese herbs could be the choices of those patients.

Key words: Colorectal neoplasms, Surgical procedures, operative, Liver metastasis, Interventional therapy, Radiotherapy

Miao Yu, Yiping Lu. A review of therapies of liver metastasis from colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(06): 523-527.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.06.014

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I06/523

References 43

[1]	汤钊猷. 现代肿瘤学[M]. 第2版. 上海: 上海医科大学出版社, 2000, 775-818.
[2]	NCCN. Clinical practice guidelines in Oncology: colon cancer (2016.V2)[EB/OL]. NCCN, 2015[2015-11-24]. URL
[3]	Zalinski S,Mariette C,Farges O, et al. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version[J]. J Visc Surg, 2011, 148(3): e171-182.
[4]	Ruers T,Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results[J]. Eur J Cancer, 2002, 38(7): 1023-1033.
[5]	施东华,王小林. 大肠癌肝转移机制及诊治进展[J].中国医学计算机成像杂志. 2010, 16(1): 81-86.
[6]	郁宝铭. 结直肠癌肝转移的外科防治[J]. 腹部外科, 2000, 13(1): 22-24.
[7]	Dexiang Z,Li R,Ye W, et al. Outcome of patients with colorectal liver metastasis: analysis of 1, 613 consecutive cases[J]. Ann Surg Oncol, 2012, 19(9): 2860-2868.
[8]	朱德祥,任黎,许剑民.不可切除结直肠癌肝转移的转化性治疗策略[J].中国实用外科杂志, 2013, 33(8): 635-644.
[9]	Bolton JS,Fuhman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma[J]. Ann Sury, 2000, 231 (5): 743-751.
[10]	Lochan R,White SA,Manas DM. Liver resection for colorectal liver metastasis[J]. Surg Oncol, 2007, 16(1): 33-45.
[11]	邱云峰,许海民,陈虹, 等. 大肠癌肝转移的诊断及外科治疗(附32例报告)[J]. 中国医师进修杂志, 2006, 29(11): 40-41, 43.
[12]	谭桂兴. 大肠癌肝转移的诊断与治疗[J]. 中华现代医学与临床, 2007, 6(6): 20-21.
[13]	Adam R,Hoti E,Folprecht G, et al. Accomplishments in 2008 in the management of curable metastatic colorectal cancer[J]. Gastrointest Cancer Res, 2009, 3(5 Supplement 2): S15-22.
[14]	Zalinski S,Mariette C,Farges O, et al. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version[J]. J Visc Surg, 2011, 148(3): e171-182.
[15]	Kopetz S,Chang GJ,Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy[J]. J Clin Oncol, 2009, 27(22): 3677-3683.
[16]	中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 结直肠癌诊疗规范(2015年版)[J]. 中华外科杂志, 2015, 53(12): 881-894.
[17]	罗威等. 结肠癌同时性肝转移同期手术与分期手术的疗效比较[J]. 中国普通外科杂志, 2013, 22(4): 434-437.
[18]	王庆新,徐斌,晏建军, 等. 同时性结直肠癌肝转移患者治疗策略探讨[J]. 癌症, 2008, 27(7): 748-751
[19]	Andreou A,Aloia TA,Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastasesin the era of modern chemotherapy[J]. Ann Surg, 2013, 257(6): 1079-1088.
[20]	Angelsen JH,Horn A,Eide GE, et al. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival[J]. World J Surg Oncol, 2014, 12(1): 127.
[21]	Mise Y,Kopetz S,Mehran RJ, et al. Is complete liver resection without resection of synchronous lung metastases justified?[J]. Ann Surg Oncol, 2015, 22(5): 1585-1592.
[22]	Adam R,Del Gaudio M. Evolution of liver transplantation for hepatocellular carcinoma[J]. J Hepatol, 2003, 39(6): 888-895.
[23]	Schadde E,Ardiles V,Robles-Campos R, et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry[J]. Ann Surg. 2014, 260(5): 829-836.
[24]	王征,樊嘉,周俭. ALPPS在肝脏外科的应用前景[J]. 肝胆外科杂志, 2015, 23(1): 1-2.
[25]	Poston G,Adam R,Vauthey JN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer[J]? J Clin Oncol, 2006, 24(18): 2702-2706.
[26]	中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠肛门外科学组, 中国抗癌协会大肠癌专业委员会. 结直肠癌肝转移诊断和综合治疗指南(V 2013)[J]. 中华胃肠外科杂志, 2013, 16(8): 780-788.
[27]	Leichman L. The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer[J]. Surg Oncol Clin N Am, 2007, 16(3): 537-556.
[28]	Van Cutsem E,Nordlinger B,Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-2221.
[29]	NCCN. Clinical practice guidelines in Oncology(2009.V2)[EB/OL]. NCCN, 2009. URL
[30]	Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases[J]. Ann Oncol, 2003, 14(Suppl 2): ii13-16.
[31]	Folprecht G,Grothey A,Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates[J]. Ann Oncol, 2005, 16(8): 1311-1319.
[32]	Coskun U,Buyukberber S,Yaman E, et al. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients[J]. Neoplasma, 2008, 55(1): 65-70.
[33]	Ismaili N. Treatment of colorectal liver metastases[J]. World J Surg Oncol, 2011, 9: 154.
[34]	Masi G,Vasile E,Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis[J]. J Natl Cancer Inst, 2011, 103(1): 21-30.
[35]	Vauthey JN,Pawlik TM,Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases[J]. J Clin Oncol, 2006, 24(13): 2065-2072.
[36]	Wong R,Cunningham D,Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection[J]. Ann Oncol, 2011, 22(9): 2042-2048.
[37]	Gruenberger B,Tamandl D,Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(11): 1830-1835.
[38]	Petrelli F,Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis[J]. Int J Colorectal Dis, 2012, 27(8): 997-1004.
[39]	Leone F,Artale S,Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study[J].Cancer, 2013, 119(19): 3429-3435.
[40]	Adam R,Wassell P,Murchie P. Why do patients with cancer access out-of-hours primary care? A retrospective study[J]. Br J Gen Pract, 2014, 64(619): e99-104.
[41]	NCCN. Clinical practice guidelines in Oncology: colon cancer(2015.V2)[EB/OL]. NCCN, 2014[2014-10-03]. URL
[42]	Clark ME,Smith RR. Liver-directed therapies in metastatic colorectal cancer[J]. J Gastrointest Oncol, 2014, 5(5): 374-387.
[43]	孙燕, 石远凯. 临床肿瘤内科手册[M].第5版.北京:人民卫生出版社, 2007.

Please choose a citation manager

Content to export